| Ytd | 7.00% | |
| 1y | -25.17% |
| Open | 0.99 | Prev Close | 0.98 | Low | 0.98 | High | 1.08 | Mkt Cap | 69.93M |
| Vol | 1.68M | Avg Vol | 886.23K | EPS | -0.96 | P/E | N/A | Forward P/E | -2.33 |
| Beta | 0.78 | Short Ratio | 9.02 | Inst. Own | 86.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.06 | 200-d Avg | 1.23 | 1yr Est | 12.14 |
TCRX News
Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the develo
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeu
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.22) per share which missed the ana
Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform a
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.18) per share which beat the analy
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercia
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the develo
HC Wainwright & Co. analyst Andres Y. Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) wi
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which beat the analy
Needham analyst Gil Blum maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the pri
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the develo
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which met the analys
HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.26) per share which beat the analy
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $9
Barclays analyst Peter Lawson maintains TScan Therapeutics (NASDAQ:TCRX) with a Overweight and lo
HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Bu
Needham analyst Gil Blum maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the pri
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.30) per share which missed the ana
TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extend
ZCAR: 193% | Zoomcar Reports 43% Booking Surge, Revamps Website Ahead of Holiday Rush ADD: 161% | Co
HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Bu
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $11
TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acut
HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Bu
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $11
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.25) per share which beat the analy
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $11
All TSC-treated patients were relapse-free and MRD negative as of data cutoffTSC-100 and TSC-101 dem
Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform
HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Bu